miRNA Signature in Early-stage Mycosis Fungoides.
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
04 Oct 2022
04 Oct 2022
Historique:
pubmed:
6
7
2022
medline:
6
10
2022
entrez:
5
7
2022
Statut:
epublish
Résumé
Altered miRNA expressions are assigned pathogenic properties in several cancers including mycosis fungoides and could play a role in the early onset of the disease. The aim of this study was to examine disease-specific miRNA expression in early-stage mycosis fungoides patch and plaque lesions. A quantitative real-time PCR platform of 384 human miRNAs was used to study miRNA expression in 154 diagnostic mycosis fungoides biopsies. A total of 110 miRNAs were significantly differentially expressed (>2-fold, p < 0.05) between plaque lesions and healthy controls, and 90 miRNAs (>2-fold, p < 0.05) differed between patch lesions and healthy controls. Moreover, 13 miRNAs differed in expression between patch and plaque lesions. Early-stage mycosis fungoides exhibited miRNA features that overlapped with those of psoriasis. However, 39 miRNAs, including miR-142-3p, miR-150 and miR-146b, were specific to mycosis fungoides. In conclusion, early-stage mycosis fungoides expresses a distinct miRNA profile, indicating that miRNAs could play a role in the early development of mycosis fungoides.
Identifiants
pubmed: 35788691
doi: 10.2340/actadv.v102.628
pmc: PMC9677281
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
adv00785Références
Oncotarget. 2015 Aug 21;6(24):20555-69
pubmed: 26244872
Int J Oncol. 2017 Feb;50(2):345-355
pubmed: 28000852
Oncotarget. 2016 Jul 19;7(29):45730-45744
pubmed: 27329723
Blood. 2011 Nov 24;118(22):5891-900
pubmed: 21865341
Exp Dermatol. 2012 Apr;21(4):299-301
pubmed: 22417307
Clin Transl Oncol. 2021 Feb;23(2):257-264
pubmed: 32524269
Exp Mol Pathol. 2018 Feb;104(1):98-107
pubmed: 29337244
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
Cancers (Basel). 2020 May 13;12(5):
pubmed: 32414221
Toxins (Basel). 2013 Aug 14;5(8):1402-21
pubmed: 23949004
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Am J Dermatopathol. 2014 Dec;36(12):933-48; quiz 949-51
pubmed: 25415138
Blood. 2019 Sep 26;134(13):1072-1083
pubmed: 31331920
Blood. 2013 Nov 14;122(20):3511-20
pubmed: 24062018
Am J Transl Res. 2017 May 15;9(5):2394-2402
pubmed: 28559989
Blood. 2018 Feb 15;131(7):759-770
pubmed: 29208599
Curr Opin Hematol. 2014 Jul;21(4):276-82
pubmed: 24870972
Lancet. 1981 Aug 8;2(8241):283-5
pubmed: 6114327
Mol Oncol. 2011 Jun;5(3):273-80
pubmed: 21406335
Nat Rev Genet. 2012 Apr 18;13(5):358-69
pubmed: 22510765
Cell Death Dis. 2013 Jun 20;4:e684
pubmed: 23788041
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
PLoS One. 2013 Aug 22;8(8):e71978
pubmed: 23991015
Blood. 1997 Jan 1;89(1):32-40
pubmed: 8978274
Blood. 2016 Mar 10;127(10):1287-96
pubmed: 26738536
Br J Dermatol. 2008 Jul;159(1):105-12
pubmed: 18489588
Blood. 2010 Aug 19;116(7):1105-13
pubmed: 20448109
J Clin Oncol. 2010 Nov 1;28(31):4730-9
pubmed: 20855822
Mol Med Rep. 2018 Jun;17(6):7529-7536
pubmed: 29620260
J Invest Dermatol. 2015 Apr;135(4):1128-1137
pubmed: 25405321
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Blood. 2009 May 21;113(21):5064-73
pubmed: 19279331
Nat Genet. 2015 Sep;47(9):1011-9
pubmed: 26192916
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Anticancer Res. 2014 Dec;34(12):7207-17
pubmed: 25503151
Oncoimmunology. 2017 Mar 17;6(5):e1306618
pubmed: 28638728
J Immunol. 2013 Dec 15;191(12):6250-60
pubmed: 24227773
Blood Cancer J. 2017 Jan 20;7(1):e517
pubmed: 28106877
Blood. 2014 Jul 31;124(5):761-70
pubmed: 24957145
J Am Acad Dermatol. 2005 Dec;53(6):1053-63
pubmed: 16310068